News

The core functions of antibodies within the immune system are highly diverse and important, serving as the body’s primary defense against a variety of pathogens. These Y-shaped proteins, produced by B cells, are not only tasked with the direct neutralization of pathogens but also play a pivotal role in orchestrating a broader immune response. Through […]

The BIO International Convention 2024 was held in San Diego, CA from June 3-6. It is the largest event for biotechnology with over 18,500 industry leaders in attendance, sharing the latest advancements in the industry. The most popular topics included:  → Biointron’s Highlighted Points:  1. AI and Digital Health 2. Next Generation Biotherapeutics  3. Oncology 

Antibodies, also known as immunoglobulins, are like the body’s own defense soldiers made by our immune system to fight off invaders called antigens, which can be viruses or bacteria. These protein soldiers do more than just protect us from illnesses; they are also helpful in scientific research and medical tests because they can bind very

The field of antibody production has witnessed significant technological advancements over the past years, particularly in hybridoma technology, which remains a cornerstone for monoclonal antibody (mAb) production. Electrofusion Technology in Hybridoma Preparation Electrofusion technology can be applied as a cell engineering technique for hybridoma preparation. This method offers substantial improvements in efficiency and control over

VHHs, also known as single-domain antibodies or nanobodies, are the smallest antigen-binding fragments derived from heavy-chain-only antibodies found in camelids, such as alpacas, llamas and camels. First discovered in 1993, VHH antibody fragments offer unique characteristics which are particularly advantageous in therapeutics, diagnostics, and research tools. This is due to their small size and structure

Phage display technology is a powerful technique for antibody discovery. It is often used to identify high-affinity interactions between antibody fragments (e.g. VHHs) and target proteins for the production of monoclonal antibodies. Originally developed in the mid-1980s, phage display is a key technology for antibody engineering, drug discovery, protein-protein interactions, and vaccine development.1 By genetically

The rapid rise of antimicrobial resistance (AMR) presents a critical challenge in modern healthcare. Traditional antibiotics are becoming increasingly ineffective against resistant strains of bacteria, necessitating innovative therapeutic strategies. One promising approach is the development of antibody-antibiotic conjugates (AACs). These innovative agents use the selectivity, favorable pharmacokinetics (PK), and safety profile of antibodies, enabling the

Jonathan Ripley, IVD and MD consulting services director at IMed Consultancy discusses the role of IVDs, regulatory perspectives for their adoption and increased market access. The EU has recently proposed an extension to the transitional provisions for certain IVD devices, postponing deadlines once again. Specifically, the proposal amends Article 110 IVDR and grants additional time to

T-cell receptor (TCR)-like antibodies represent a novel and promising class of therapeutic agents that combine the specificity of T-cell receptors with the versatility of antibodies. These antibodies are designed to recognize and bind to peptide-major histocompatibility complex (pMHC) molecules, similar to TCRs, allowing them to target intracellular antigens presented on the cell surface. Mechanism of